Trial Profile
Randomized comparative study of ipragliflozin combination therapy and sitagliptin combination therapy in patients with type 2 diabetes administrating metformin
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Aug 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms NISM Study
- 29 Jun 2021 Results (n=87) of post-hoc analysis of a 52-week of the NISM Study, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 16 Jun 2020 Primary endpoint (Comparison of percentage of patients who achieve the following items 52 weeks after randomization) has not been met, as per Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association